Table 3.
Examples of clinical trials investigating BBB-related conditions.
| Study Title | Intervention/Treatment | Status (as Reported until 15 April 2022) |
ClinicalTrials.gov Identifier |
|---|---|---|---|
| Blood–Brain Barrier Permeability Study in Adults with Meningitis (NM-BBBP) | Other: ICG-PULSION Device: LiMON, Pulsion Medical Systems Other: Gadolinium (Gadovist, Bayer, Germany) |
Terminated | NCT02902588 |
| The Relevance of the Blood–Brain Barrier to Cognitive Dysfunction and Alzheimer’s Disease | Diagnostic Test: Contrast agent enhanced MRI using Gadovist | Completed | NCT04093882 |
| Blood–Brain-Barrier Opening Using Focused Ultrasound with IV Contrast Agents in Patients With Early Alzheimer’s Disease (BBB-Alzheimers) | Device: BBB opening | Completed | NCT02986932 |
| Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM | Procedure: Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB) | Recruiting | NCT03630289 |
| Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | Procedure: Laparoscopically harvested omental free flap | Recruiting | NCT04222309 |
| Blood–Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients with Amyotrophic Lateral Sclerosis | Device: Blood–Brain Barrier opening with MRgFUS | Active, not recruiting | NCT03321487 |
| The Level of Blood–Brain Barrier Damage Biomarker in Acute Ischemic Stroke | Diagnostic Test: the level of biomarker in blood | Recruiting | NCT05321225 |
| Non-invasive Blood–Brain Barrier Opening in Alzheimer’s Disease Patients Using Focused Ultrasound | Device: Neuronavigation-guided single-element focused ultrasound transducer Drug: Definity Other: Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents Other: Positron Emission Tomography (PET) Other: Amyvid |
Recruiting | NCT04118764 |
| Blood–Brain Barrier Penetration of Therapeutic Agents in Human (BRIAN) | Drug: ODM-104 Drug: Paracetamol |
Completed | NCT04571996 |
| A Study to Evaluate Temporary Blood–Brain Barrier Disruption in Patients with Parkinson’s Disease Dementia | Device: MR Guided Focused Ultrasound Blood Brain Barrier Disruption using FUS Other Name: ExAblate |
Active, not recruiting | NCT03608553 |
| ExAblate Blood–Brain Barrier Opening for Treatment of Alzheimer’s Disease | Device: Blood Brain Barrier (BBB) Disruption | Recruiting | NCT03739905 |
| ExAblate Blood–Brain Barrier (BBB) Disruption for the Treatment of Alzheimer’s Disease | Device: Blood Brain Barrier (BBB) Disruption | Recruiting | NCT03671889 |
| Blood Brain Barrier Dysfunction and Postoperative Neurocognitive Disorders (BBBSx) | Diagnostic Test: Brain Imaging Diagnostic Test: Cognitive Testing Diagnostic Test: Blood Biomarkers |
Recruiting | NCT04566562 |
| Ultrasound-based Blood–Brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma (SC9/ABX) | Device: Sonication for opening of blood–brain barrier Drug: Chemotherapy, albumin-bound paclitaxel |
Recruiting | NCT04528680 |
| Safety Study of the Repeated Opening of the Blood–Brain Barrier with the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients (SONOKID) | Device: SonoCloud® (9 transducers) | Not yet recruiting | NCT05293197 |
| Developing Advanced Blood–Brain Barrier Permeability Imaging for Early AD | Device: GRASP DCE-MRI Device: 3T Brain Scan |
Recruiting | NCT03389698 |